
Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



02 AUG 14 PM 1:59

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Pharmaceutical Research &	Manufacturers of Amer	ica		
2. Registrant Address				
	State/Zip (or Country)	DC 20005	USA	
 Principal Place of Business (if differer City 	t trom line 2) State/Zip (or Country)			
Contact Name	Telephone E-r	nail (optional)	<u></u>	5. Senate ID #
Matthew B. Van Hook		vanhook@phrma.org		31350-12
7. Client Name 🔀 Self				6. House ID # 30654000
Check if this filing amends a particle. Check if this is a Termination l	reviously filed version of temperature.	ion Date		` •
Check if this filing amends a particle. Check if this is a Termination leading.	reviously filed version of the Report >> Terminate SES - Complete Eith	this report ion Date	÷ 13	11. No Lobbyi
Check if this filing amends a particle. Check if this is a Termination lands of the company of	reviously filed version of the Report >> Terminate SES - Complete Either Firms	this report ion Date er Line 12 OR Line	2 13 13. Org	11. No Lobbyi anizations
Check if this filing amends a property of the complex of the compl	reviously filed version of the Report >> Terminate SES - Complete Either Firms	ion Date er Line 12 OR Line EXPENSES relation	2 13 13. Org	Year End (July 1-Dec 11. No Lobbyi ganizations g activities for this repo
Check if this filing amends a property of the complex of the compl	reviously filed version of the Report >> Terminate SES - Complete Either Firms	er Line 12 OR Line EXPENSES relating period were:	2 13 13. Org	11. No Lobbyi
Check if this filing amends a process. Check if this is a Termination Income or Expension 12. Lobbying 12. Lobbying 12. Lobbying accepted was: Less than \$10,000 \$10,000 or more \$\sum >> \$\sum Provide a good faith estimate, round the composition of the	Report >> Terminat SES - Complete Eith Firms tivities for this reporting Income (nearest \$20,000)	er Line 12 OR Line EXPENSES relating period were: Less than \$10,000 \$10,000 or more 14. REPORTING	13. Org 13. Org 13. S METHOD.	11. No Lobbyi ganizations g activities for this repo \$6,200,000.00 Expenses (nearest \$20,000.00) Check box to indicate
Check if this filing amends a property of the content of the conte	Report >> Terminat SES - Complete Eith Firms tivities for this reporting Income (nearest \$20,000) Inded to the nearest come from the client strant by any other entity	er Line 12 OR Line EXPENSES relating period were: Less than \$10,000 \$10,000 or more 14. REPORTING accounting method.	13. Org 13. Org 13. Org S >> \$ METHOD. See instruction	\$6,200,000.00 Expenses (nearest \$20,000.00 for description of comparison of compariso
O. Check if this is a Termination Income or Expension 12. Lobbying INCOME relating to lobbying acperiod was: Less than \$10,000	Report >> Terminat SES - Complete Eith Firms tivities for this reporting Income (nearest \$20,000) Inded to the nearest come from the client strant by any other entity	er Line 12 OR Line EXPENSES relating period were: Less than \$10,000 \$10,000 or more 14. REPORTING accounting method. Method A. Re Method B. Re	13. Org 13. Org 13. Org 13. Org 13. Org 14. See instructions 15. See instructions 16. See instructions 17. Org 18. Org 19. Org	\$6,200,000.00 Expenses (nearest \$20,000.00 for description of our of the construction

1 miles manie and 1 me _	· - · · · · · · · · · · · · ·	The Comment continue	 Pag	зе

Regi	istrant Name:	Pharmaceutical Research & Manufact	urers of America
Clie	nt Name:	Self	
enga	iged in lobbyin	· · · · · · · · · · · · · · · · · · ·	to reflect the general issue areas in which the registrant ag period. Using a separate page for each code, provide.
15.	General issue	area code BUD (one per page)	
16.	H.R. 2330, A 2002; , FDA H.R. 3061, L S. 1191, Agri	griculture, Rural Development, Food an Appropriations abor-HHS Appropriations, 2002; , NIH	Drug Administration, and Related Agencies Appropriat
17.	Department	Congress and Federal agencies contacted of Health & Human Services and Administration oresentatives	☐ Check if None
18.	Name of each	a individual who acted as a lobbyist in this i	issue area
	Name		Covered Official Position (if applicable)
	Bantham, R	ussel	
	Currie, Rod	ger	
	Deschenes, F	llise	Legislative Assistant, Rep. George Nethercutt, Jr.
	Guarducci, I	Mara.	
	Holmer, Ala	n F.	
	Jenkins, Mis	sy	
	Mohler, Dav	e T.	
19.	Interest of ea	ch foreign entity in the specific issues listed	l on line 16 above 🛮 🗷 Check if None
Sim	12ftire		Date 8/9/02

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name:

Self

Item Descrip		Data
1 *	st Name	Olsen, Scott
18b Covere	d Official Position	
18c New Lo	bbyist	No
18a Lobbyi	st Name	Pomfret, Jacqui
18b Covere	d Official Position	•
18c New Lo	bbyist	No
18a Lobbyi:	st Name	Rubin, Peter
18b Covere	d Official Position	Legislative Director for Rep. Jim McDermott
18c New Lo	bbyist	No
18a Lobbyi	st Name	Sotak, Sonya
18b Covere	d Official Position	Legislative Assistant, Sen. John McCain
18c New Lo	bbyist	Yes
18a Lobbyi	st Name	Van Hook, Matthew B.
•	d Official Position	•
18c New Lo	bbyist	No

Reg	istrant Name:	Pharmaceutical Research & Manufact	urers of America
Clie	nt Name:	Self	
enga	iged in lobbyin	· · · · · · · · · · · · · · · · · · ·	to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide.
15.	General issue	area code <u>CPT</u> (one per page)	
16.	H.R. 2047, P. S. 754, Drug	oying issues ffordable Prescription Drugs and Medic atent and Trademark Office Authorizat Competition Act of 2001, .R. 1862, Greater Access To Affordable	ion Act of 2002,
17.	House of Rep	Congress and Federal agencies contacted presentatives trademark Office	☐ Check if None
18.	Name of each	individual who acted as a lobbyist in this	issue area Covered Official Position (if applicable)
	Bantham, Ru	ıssel	
	Currie, Rodg	ger	
	Guarducci, N	Mara	Legislative Assistant, Rep. Jim Greenwood
	Holmer, Alai	n F.	
	Mohler, Dav	e T.	
	Olsen, Scott		
	Pomfret, Jac	qui	
19.	Interest of eac	ch foreign entity in the specific issues listed	l on line 16 above 🔀 Check if None
Sion	nature		Date 8/9/02

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Sotak, Sonya
18b	Covered Official Position	Legislative Assistant, Sen. John McCain
18c	New Lobbyist	Yes
18a	Lobbyist Name	Van Hook, Matthew B.
18b	Covered Official Position	
18c	New Lobbyist	No

Registrant Na	ame: Pharmaceutical Research & Manuf	acturers of America
Client Name:	Self	<u> </u>
LOBBYING engaged in lo information a 15. General 16. Specific H.R. 13 H.R. 14 H.R. 16 H.R. 17 prescrip H.R. 28 H.R. 34 H.R. 58 H.R. 68 of Presc	ACTIVITY. Select as many codes as necessabbying on behalf of the client during the reposit requested. Attach additional page(s) as need issue area code HCR (one per page Lobbying issues 187, Drug Availability and Health Care Accessory, Drug Availability and Bioterroris and Bioterroris and Medicine Equity and Drug Safety Act Cosmetic Transport of the Pood, Drug, and Cosmetic	tess Improvement Act of 2001, Act of 2001, price controls on drugs for Medicare benefic 1, eterans Affairs pharmacies to dispense medications to vet , m Response Act of 2001, rrections of 2000, restrain FDA regulation of drug import Act relating to the distribution chain of prescription drug e pedigree requirements for unauthorized distributors
17. House(s Departs Food &	s, Personal Prescription Drug Import Fairn s) of Congress and Federal agencies contacted ment of Health & Human Services s Drug Administration of Representatives	
18. Name o	f each individual who acted as a lobbyist in th	nis issue area Covered Official Position (if applicable)
Rantha	ım, Russel	
	, Rodger	
Desche	nes, Elise ucci, Mara.	Legislative Assistant, Rep. George Nethercutt, Jr.
Holmer	r, Alan F.	
Jenkins	s, Missy	
Lucas,	William	
19. Interest	of each foreign entity in the specific issues li	sted on line 16 above 🔀 Check if None
Signature		Date 8/9/02

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name:

<u>Self</u>

Item	Description	Data
16	Lobbying Issues	S. 1032, International Infectious Diseases Control Act of 2001, expansion of
		assistance to countries seriously afffected by HIV/AIDS, Malaria and Tubere
16	Lobbying Issues	S. 1120, Global AIDS Research and Relief Act of 2001, expansion of FY02
		appropriations and authorization of FY03 appropriations to combat HIV/AI
16	Lobbying Issues	S. 1132, To amend the Food, Drug, and Cosmetic Act relating to the distribu
		chain of prescription drugs, relaxation of Prescription Drug Marketing Act.
16	Lobbying Issues	S. 1765, Bioterrorism Preparedness Act of 2001,
16	Lobbying Issues	S. 1789, Best Pharmaceuticals for Children Act,
6	Lobbying Issues	S. 215, Medication Equity and Drug Savings Act,
16	Lobbying Issues	S. 2244, Prescription Drug Price Parity for Americans Act,
16	Lobbying Issues	S. 2394, Pediatric Labeling of Drugs and Biological Products,
16	Lobbying Issues	S. 699, Prescription Drug Fairness for Seniors Act of 2001, price controls on
1.6	Lobbying Issues	for Medicare beneficiaries.
16 16	Lobbying Issues Lobbying Issues	S. 812 and H.R. 1862, Greater Access To Affordable Pharmaceuticals Act, S. 838, Best Pharmaceuticals for Children Act,
16 16	Lobbying Issues Lobbying Issues	S. 838, Best Pharmaceuticals for Children Act, Reauthorization of the Prescription Drug User Fee Act
10 16	Lobbying Issues Lobbying Issues	Executive Branch:
v	Founding 199069	FDA implementation of P.L. 105-115, the FDA Modernization Act of 1997;
		Reauthorization of the Prescription Drug User Fee Act
18a	Lobbyist Name	Mohler, Dave T.
18b	Covered Official Position	,
18c	New Lobbyist	No
l8a	Lobbyist Name	Olsen, Scott
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Pomfret, Jacqui
18b	Covered Official Position	1 vinited vacque
18c	New Lobbyist	No
l8a	Lobbyist Name	Reilly, Lori
8b	Covered Official Position	Acting the state of the state o
18c	New Lobbyist	No
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
8a	Lobbyist Name	Sotak, Sonya
8b	Covered Official Position	Legislative Assistant, Sen. John McCain
8c	New Lobbyist	Yes
l8a	Lobbyist Name	Van Hook, Matthew B.
	Covered Official Position	
8b 8c	New Lobbyist	No

Regi	istrant Name:	Pharmaceutical Research & Manufacturers of America
Clie	nt Name:	Self
enga	nged in lobbying	IVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant g on behalf of the client during the reporting period. Using a separate page for each code, provide ested. Attach additional page(s) as needed.
	General issue	· · · · · · · · · · · · · · · · · · ·
16.	S. 1177, Acces S. 1239, Medicard. S. 357, Medic S. 358, Medic S. 925, Medic Executive Bra	edicare Modernization and Prescription Drug Act of 2002, ss to Affordable Prescription Drugs Act of 2001, icare Rx Drug Discount and Security Act of 2001, to provide Medicare beneficiaries with a dructure Prescription and Improvement Act of 2001 (Breaux-Frist I), care Prescription Drug and Modernization Act of 2001 (Breaux-Frist II), care Extension of Drugs to Seniors (MEDS) Act of 2001,
17.		ongress and Federal agencies contacted Check if None Financing Administration, Dept. of Health and Human Services oresentatives
18.	Name of each	individual who acted as a lobbyist in this issue area Covered Official Position (if applicable)
	Currie, Rodg	er
	Guarducci, M	1ara.
	Holmer, Alan	ı F.
	Jenkins, Miss	SY
	Lucas, Willia	
	Mohler, Dave	
	Olsen, Scott	
19.		ch foreign entity in the specific issues listed on line 16 above Check if None
Sign	nature	Date

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
18a	Lobbyist Name	Pomfret, Jacqui
18b	Covered Official Position	·
18c	New Lobbyist	No
18a	Lobbyist Name	Reilly, Lori
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Sotak, Sonya
18b	Covered Official Position	Legislative Assistant, Sen. John McCain
18c	New Lobbyist	Yes

Reg	istrant Name:	Pharmaceutical Research & Manufact	urers of America
Clie	nt Name:	Self	
enga	iged in lobbyin	*	to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide.
15.	General issue	area code TAX (one per page)	
16.	& developme H.R. 41 and to increase the S. 2486, Fair Department	conomic Growth and Tax Relief Reconcent tax credit. S. 41, A bill to To amend the Internal Rene rates of the alternative incremental cradvertising and Increased Research (F.)	
17.		Congress and Federal agencies contacted presentatives	☐ Check if None
18.	Name of each	n individual who acted as a lobbyist in this	issue area Covered Official Position (if applicable)
	Currie, Rod	ger	
	Guarducci, I	Mara.	
	Holmer, Ala	n F.	
	Rubin, Peter	•	Legislative Director for Rep. Jim McDermott
	Van Hook, N		1
<u> </u>			
			
19.	Interest of ea	ch foreign entity in the specific issues listed	
Sig	nature		Date _ 8/9/02

Printed traine and time	 — - <u>r</u> , —	Ti.

Registrant Name: Pharmaceutical Research & Manufacturers of America							
Client Name:		Self					
enga	LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.						
15.	General issue	area code TRD (one per page)					
16.	6. Specific Lobbying issues H.R. 1185, Global Access to HIV/AIDS Medicines Act of 2001, H.R. 2069, Global Access to HIV/AIDS Prevention, Awareness, Education, and Treatment Act of 2001, H.R. 2603, United States-Jordan Free Trade Area Implementation Act, H.R. 3009, Trade Act of 2002, H.R. 933, Affordable HIV/AIDS Medicines for Poor Countries Act, Executive Branch: Strengthening protection of Intellectual property abroad.						
17.	House(s) of Congress and Federal agencies contacted Department of Commerce House of Representatives Office of the United States Trade Representative Senate						
18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable)							
	Currie, Rod	ger.					
	Herzfeld, Sl						
	Holmer, Ala	n F.					
	Lucas, Willi	am					
	Mohler, Da	ve T.					
	Olsen, Scott						
	Pomfret, Ja	cqui					
19.	Interest of ea	ach foreign entity in the specific issues listed	l on line 16 above 🔀 Check if None				
Sion	nature		Date8/9/02				

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name:

Self

Item	Description	Data	
18a	Lobbyist Name	Rubin, Peter	
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott	
18c	New Lobbyist	No	
18a	Lobbyist Name	Sotak, Sonya	
18b	Covered Official Position	Legislative Assistant, Sen. John McCain	
18c	New Lobbyist	Yes	

Registrant Name: Pharmaceutical Research & Manufacturers of America								
Client Name:	Self		, od. 2 /r					
Information \	Update Page - C	omplete ONLY whe	re registration information h	as changed.				
20. Client new add	ress	- 						
21. Client new prin	21. Client new principal place of business (if different from line 20)							
City		State/Zip (or Country)						
22. New general de	scription of client's busines	ss or activities						
LOBBYIST U		·						
23. Name of eac Stewart, Sh		d individual who is n o	o longer expected to act as a lo	bbyist for the client				
ISSUE UPDA'	re							
		ly reported that no lo	enger pertain					
A EDII IATED	ORGANIZATIO	NC		<u></u>				
	lowing affiliated orga							
	Name		Address	Principal Place of Bus (city and state or cou				
26. Name of ea	ch previously reporte	d organization that is	no longer affiliated with the re	egistrant or client				
			A Decision of the Control of the Con					
FOREIGN EN 27. Add the fol	NTITIES lowing foreign entitie	es .	4-14-14					
Name		Address	Principal Place of Busines (city and state or country)					
	ch previously reporte l organization	d foreign entity that	no longer owns, or controls, or	r is affiliated with the registra				
		1.		0.015				
Signature	5. h	Har		Date <u>8/9/02</u>				

Th...
